175 related articles for article (PubMed ID: 32306527)
1. SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis.
Di Cesare A; Tronconi G; Fastame TM; Rosi E; Pescitelli L; Ricceri F; Prignano F
Dermatol Ther; 2020 May; 33(3):e13435. PubMed ID: 32306527
[No Abstract] [Full Text] [Related]
2. Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: An open-labeled, prospective, pilot case series.
Khandpur S; Sondhi P; Taneja N; Sharma P; Das D; Sharma A; Sreenivas V
J Am Acad Dermatol; 2020 Jul; 83(1):248-251. PubMed ID: 32087993
[No Abstract] [Full Text] [Related]
3. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
[TBL] [Abstract][Full Text] [Related]
4. SB5: An Adalimumab Biosimilar.
Frampton JE
BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
[TBL] [Abstract][Full Text] [Related]
6. The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.
Müller-Ladner U; Dignass A; Gaffney K; Jadon D; Matucci-Cerinic M; Lobaton T; Carron P; Gisbert JP; Pande I; Utzinger M; Addison J
BioDrugs; 2023 Nov; 37(6):873-889. PubMed ID: 37632666
[TBL] [Abstract][Full Text] [Related]
7. Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi
Gisbert JP; Gaffney K; Young D; Ebbers HC; Girolomoni G
Expert Opin Biol Ther; 2022 Feb; 22(2):109-121. PubMed ID: 34918591
[TBL] [Abstract][Full Text] [Related]
8. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J
Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421
[TBL] [Abstract][Full Text] [Related]
9. Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study.
Giunta A; Manfreda V; Esposito M; Del Duca E; Bianchi L
Br J Dermatol; 2019 Nov; 181(5):1078-1079. PubMed ID: 31049938
[No Abstract] [Full Text] [Related]
10. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
Zhao S; Chadwick L; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up.
Kurizky PS; Galvão LO; Martins GA
An Bras Dermatol; 2019; 94(4):483-484. PubMed ID: 31644629
[No Abstract] [Full Text] [Related]
12. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis.
Nielsen VW; Lund TT; Gniadecki R; Olsen RH; Nissen CV; Schwensen JFB; Thomsen SF
Dermatol Ther; 2020 Nov; 33(6):e14258. PubMed ID: 32865289
[No Abstract] [Full Text] [Related]
14. Pyoderma gangrenosum induced by adalimumab in a seropositive rheumatoid arthritis patient: a paradoxical effect of adalimumab?
Tan Y; Kavaklieva S; Wood F
Rheumatology (Oxford); 2021 Aug; 60(8):e288-e289. PubMed ID: 33836074
[No Abstract] [Full Text] [Related]
15. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.
Papoutsaki M; Costanzo A; Chimenti MS; Chimenti S
Expert Opin Biol Ther; 2008 Mar; 8(3):363-70. PubMed ID: 18294106
[TBL] [Abstract][Full Text] [Related]
16. GP2015: An Etanercept Biosimilar.
Deeks ED
BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
[TBL] [Abstract][Full Text] [Related]
17. Real-life Safety Profile of ZRC3197 (Adalimumab Biosimilar) in Indian Patients with Common Rheumatic Diseases.
Mathew AJ; Ganapati A; T SK; Goel R; P S; Danda D
J Assoc Physicians India; 2017 May; 65(5 Suppl):30-32. PubMed ID: 28836749
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.
Mengato D; Messori A
Clin Exp Rheumatol; 2018; 36(6):1118. PubMed ID: 29600941
[No Abstract] [Full Text] [Related]
19. Arthritis possibly induced and exacerbated by a tumour necrosis factor antagonist in a patient with psoriasis vulgaris.
Takahashi T; Asano Y; Shibata S; Nakamura K; Nakao M; Shida R; Mitsui A; Araki M; Watanabe R; Fujita H; Tada Y; Sato S
Br J Dermatol; 2015; 172(5):1458-60. PubMed ID: 25565011
[No Abstract] [Full Text] [Related]
20. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis.
Stiff KM; Glines KR; Porter CL; Cline A; Feldman SR
Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1209-1218. PubMed ID: 30449211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
